# Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Source: https://onco.cc/trials/nct06719973/  
OnCo record `nct06719973` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is withdrawn.

## Summary

The registry lists NCT06719973 as withdrawn, last updated 2025-06-17. Enrolment is 0 actual participants. Interventions: M9466, Carboplatin, Etoposide, Atezolizumab, M9446. Primary measures include Module 1 and Module 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs; Module 1 and Module 2: Number of Participants with Dose-limiting Toxicity (DLT). The registry reason for stopping is: Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT06719973
- Phase: 1
- Setting: An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 0

## Sources

- ClinicalTrials.gov NCT06719973: https://clinicaltrials.gov/study/NCT06719973

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct06719973.json